Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Glioblastoma 2Breast Neoplasms 2Brain Neoplasms 2Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Gliosarcoma 1Colorectal Neoplasms 1

Interventions

pembrolizumab 3Docetaxel 3Cisplatin 3Erlotinib Hydrochloride 2Cetuximab 2Carboplatin 2spartalizumab 1ixabepilone 1entrectinib 1Vorinostat 1Tablets 1Radiotherapy 1Radiosurgery 1RC48 antibody 1Paclitaxel 1Nivolumab 1NVP-BKM120 1Ipilimumab 1Gemcitabine 1Fluorodeoxyglucose F18 1FPP(RGD)2 1Everolimus 1Epirubicin 1Combined Modality Therapy 1Chemoprevention 1Capecitabine 1CTLA-4 Antigen 1Bevacizumab 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Salivary Gland Neoplasms × NVP-BKM120 × Clear all
NCT01816984 2021-10-05

PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

University of Chicago

Phase 1/2 Completed
12 enrolled 11 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡